06.18.24 -- ADCs Ignited With Daiichi Sankyo Inc.'s Ken Keller

Being aware and proactive in addressing IP risks and challenges, especially for drug developers and sponsors operating in Asia, is critical. Delve into the IP landscape of several Asian countries.

Increased investment in allogeneic therapies and process-level advancements to achieve commercial scale are paving the way for streamlined, standardized cell therapy development and manufacturing.

Market dynamics will continue to favor engaging with CDMO partners who have the capabilities and experience to manage short-term needs while anticipating and planning for long-term requirements.

Explore the benefits of using mRNA for vaccines and therapeutics, and learn how to address technical, intellectual property, and cost considerations when considering commercial production.

There are several important factors that developers and manufacturers will need to consider to effectively support antibody therapeutics and navigate the trends and challenges on the horizon.

Biopharmaceutical tech transfer, critical to the successful development and manufacture of an asset, requires careful planning and evaluation to meet project timelines for scale up and GMP.

Ensure a smooth transition from development to manufacturing by implementing a strategic tech transfer process. Review key practices for effective communication, collaboration, and risk mitigation.

For small and midsize biopharmaceutical organizations, outsourcing buffer and process liquid preparation, quality testing, and storage could significantly streamline operations and reduce risk.

Learn how finding the right combination of capabilities and expertise in a CDMO can set you up for success and keep your innovative project on time and within budget.